NRX Pharmaceuticals, Inc. current report, 21 May 2021

Full document

Business Context and Reporting Period

This Form 8-K is filed by Big Rock Partners Acquisition Corp. (BRPA) on May 21, 2021. The filing announces the effectiveness of the registration statement on Form S-4 regarding a proposed business combination with NeuroRx, Inc. (NRX). Under the agreement, a wholly-owned subsidiary of BRPA will merge with NeuroRx, making NeuroRx a wholly-owned subsidiary of BRPA. An annual meeting to approve the transaction is scheduled for May 24, 2021.

Key Financial Metrics

This filing is a current report regarding a corporate event and does not contain audited financial statements, revenue, profit, cash flow, or margin data for either company. The filing text does not provide a clear value for debt, liquidity, or other operational financial metrics.

Material Changes

The primary material change is the regulatory progress of the merger:

  • Effectiveness of the Form S-4 registration statement was confirmed on May 21, 2021.
  • Final proxy statements and prospectuses have been mailed to stockholders of both BRPA and NeuroRx.
  • The transaction is proceeding toward a shareholder vote scheduled for May 24, 2021.

Guidance, Outlook, and Risks

Management commentary is limited to the procedural status of the merger. The filing includes a cautionary note regarding forward-looking statements, highlighting several risks and uncertainties:

  • The outcome of discussions or applications for the future use of NeuroRx's product, ZYESAMI.
  • The ability to complete the proposed business combination.
  • The combined company's ability to maintain its listing on the Nasdaq Stock Market after the transaction closes.
  • General risks associated with future financial or operating performance.

NeuroRx does not undertake an obligation to update forward-looking statements based on new information.

Investor Verification Checklist

  • Verify the outcome of the shareholder vote scheduled for May 24, 2021.
  • Review the full Form S-4 registration statement and proxy materials for detailed transaction terms and financial projections.
  • Monitor regulatory approvals regarding the future use of ZYESAMI.
  • Confirm the post-merger listing status on Nasdaq.